LIFR and neoplasm: These findings suggest that trametinib paradoxically induces LIFR signaling in Ras/Raf-mutant OCa cells, potentially contributing to adaptive resistance, and that co-treatment with EC359 effectively suppresses this compensatory pathway, enhancing anti-tumor efficacy.